Tylenol-Maker Kenvue’s Stock Is Down 30% in 2025. Its Fate May Be in the FDA’s Hands. The former consumer health unit of Johnson & Johnson remains mired in troubles surrounding Tylenol. Barchart · Oct 22, 2025
This Billionaire Investor Is ‘Thrilled’ to Own Kenvue Stock Despite Tylenol Turbulence. Should You Buy KVUE Here? Kenvue stock is down 28% in 2025 amid controversy surrounding its Tylenol brand, which is linked to autism when used during pregnancy. Barchart · Oct 22, 2025
Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch Health care giant Johnson Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter financial results are reported before market open Tuesday. Benzinga · Oct 13, 2025
Options Corner: Despite Political Woes, Kenvue Can Still Make Tylenol Great Again Amid a contentious political environment, consumer pharmaceutical firm Kenvue Inc (NYSE:KVUE) finds itself under a harsh spotlight. Specifically, its popular drug Tylenol has attracted the ire of the White House. Late last month, President Donald Trump stated on Truth Social that pregnant women shouldn't use Tylenol unless absolutely necessary. With… Benzinga · Oct 6, 2025
Smoke from Wildfires Chokes Austin: What Locals Are Breathing Tonight Wildfire smoke blankets Austin, with haze from local and distant blazes prompting health alerts and raising questions about the city's fire readiness. International Business Times UK · Oct 6, 2025
Quadruple murder at Austin yogurt shop was one of city’s most infamous cold cases. 30 years later police have a suspect Serial killer Robert Eugene Brashers, who died by suicide in 1999, committed at least seven murders across multiple states between 1990 and 1998, prior to the Austin yogurt shop killings The Independent UK · Sep 30, 2025
As Trump Takes Aim at Tylenol, Should You Buy, Sell, or Hold Parent Company Kenvue Stock’s Here? Kenvue stock is trailing the broader markets by a wide margin in 2025 due to regulatory concerns over its flagship Tylenol product. Barchart · Sep 24, 2025
Kenvue Surges Over 2% Pre-Market Despite Trump Administration's Autism Warning Kenvue Inc. (NYSE:KVUE) saw its stock rise by 2.61% to $17.69 in pre-market trading on Wednesday, despite concerns stirred by President Trump's controversial comments about acetaminophen potentially being linked to autism. Benzinga · Sep 24, 2025
What's Going On With Kenvue Stock Tuesday? Kenvue Inc. (NYSE:KVUE) shares are trading higher Tuesday despite President Donald Trump saying the Food and Drug Administration will notify physicians that use of acetaminophen or Tylenol during pregnancy could be associated with increase risk of autism. Benzinga · Sep 23, 2025
Jim Cramer Says Trump Is Creating 'A Nightmare' For Kenvue As President Links Tylenol With Autism CNBC’s Jim Cramer warned Tuesday that President Donald Trump is creating a “nightmare of potential litigation” for consumer health giant Kenvue Inc. (NYSE:KVUE), sending the company's stock tumbling. Benzinga · Sep 23, 2025
Nvidia, Kenvue, Rivian, MicroCloud Hologram And Opendoor: Why These 5 Stocks Are On Investors' Radars Today U.S. stocks closed higher on Monday, with the Dow Jones Industrial Average edging up 0.14% to 46,381.54. The SP 500 added 0.4% to finish at 6,693.75, while the Nasdaq climbed 0.7% to 22,788.98.These are the top stocks that gained the attention of retail traders and investors through the day: Nvidia… Benzinga · Sep 23, 2025
Kenvue Stock Is Sliding Today: What's Fueling The Sell-Off? Shares of Kenvue Inc (NASDAQ:KVUE) are down Monday in anticipation of a negative Trump administration announcement about one of its products. Benzinga · Sep 22, 2025
Trump Administration To Unveil Tylenol-Autism Review, Tout This Drug As Potential Treatment: Report The Trump administration is expected to unveil new efforts on Monday examining whether one widely used drug may be linked to autism and whether another could help treat it, according to people familiar with the plans who spoke to The Washington Post on condition of anonymity because the announcement was… Benzinga · Sep 22, 2025
Kenvue Pushes To Defend Pain Killer Tylenol Against Autism Claims Ahead Of Government Report Kenvue Inc. (NYSE:KVUE) interim CEO Kirk Perry met privately this week with Health Secretary Robert F. Kennedy Jr. to argue that there is no proven link between the popular pain reliever Tylenol and autism. Benzinga · Sep 12, 2025
Barchart · Sep 11, 2025 Is Kenvue Stock Underperforming the Dow? Despite Kenvue’s recent underperformance relative to the Dow, analysts remain moderately optimistic about the stock’s prospects.
Benzinga · Sep 5, 2025 RFK Jr. To Link Tylenol Use To Autism: Report Health Secretary Robert F. Kennedy Jr. is preparing to release a report suggesting that the use of a common over-the-counter pain reliever during pregnancy may be tied to a higher risk of autism.
Barchart · Jul 30, 2025 Kenvue Stock Outlook: Is Wall Street Bullish or Bearish? Kenvue has outpaced the broader market over the past year, and analysts remain cautiously optimistic about the stock’s prospects.
Barchart · Jul 16, 2025 Kenvue Stock Has Unusual Put Option Activity After Lower Q2 Sales and CEO Firing Kenvue, which manufactures Band-Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO had left. Put options are showing unusually high volume today.
Barchart · Jul 16, 2025 Kenvue's Q2 2025 Earnings: What to Expect Kenvue is expected to release its second-quarter earnings next month, and analysts anticipate a double-digit profit dip.
Barchart · Jul 14, 2025 Tylenol-Maker Kenvue Launches Turnaround Plans. How Should You Play KVUE Stock Here? Kenvue Inc ousted its chief executive and announced a strategic review on Monday. Jefferies says KVUE shares could rally to $27.
Latin Times · Jul 10, 2025 Suspect in Fatal Hit-and-Run Killed in a Separate Car Crash Weeks Later A Texas man accused in a fatal hit-and-run died weeks later in a separate crash that also killed two Good Samaritans, prompting an ongoing investigation.
Barchart · Jun 12, 2025 Is Kenvue Stock Outperforming the Nasdaq? Despite its recent underperformance, Kenvue has outpaced the Nasdaq over the past year, and analysts remain moderately bullish on the stock’s prospects.
Barchart · May 2, 2025 Are Wall Street Analysts Predicting Kenvue Stock Will Climb or Sink? Kenvue has outpaced the broader market over the past year, and Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.
Barchart · Apr 23, 2025 Kenvue Earnings Preview: What to Expect Kenvue is set to unveil its Q1 results in the upcoming month, and analysts expect a notable decline in earnings.
MarketBeat · Apr 15, 2025 2 Under-the-Radar Consumer Staples Stocks With Big Dividends Edgewell and Kenvue are under-the-radar consumer staples stocks poised to gain as the U.S. dollar declines. Learn why they may boost your income portfolio.